JP7784993B2 - タンパク質－巨大分子コンジュゲート及びその使用方法 - Google Patents
タンパク質－巨大分子コンジュゲート及びその使用方法Info
- Publication number
- JP7784993B2 JP7784993B2 JP2022518653A JP2022518653A JP7784993B2 JP 7784993 B2 JP7784993 B2 JP 7784993B2 JP 2022518653 A JP2022518653 A JP 2022518653A JP 2022518653 A JP2022518653 A JP 2022518653A JP 7784993 B2 JP7784993 B2 JP 7784993B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- poly
- formula
- alkyl
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908435P | 2019-09-30 | 2019-09-30 | |
| US62/908,435 | 2019-09-30 | ||
| PCT/US2020/053572 WO2021067458A1 (en) | 2019-09-30 | 2020-09-30 | Protein-macromolecule conjugates and methods of use thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022549295A JP2022549295A (ja) | 2022-11-24 |
| JPWO2021067458A5 JPWO2021067458A5 (https=) | 2023-11-13 |
| JP2022549295A5 JP2022549295A5 (https=) | 2023-11-13 |
| JP7784993B2 true JP7784993B2 (ja) | 2025-12-12 |
Family
ID=75337536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518653A Active JP7784993B2 (ja) | 2019-09-30 | 2020-09-30 | タンパク質－巨大分子コンジュゲート及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220401561A1 (https=) |
| EP (1) | EP4037715A4 (https=) |
| JP (1) | JP7784993B2 (https=) |
| KR (1) | KR20220074897A (https=) |
| CN (1) | CN114630818A (https=) |
| AU (1) | AU2020360397A1 (https=) |
| BR (1) | BR112022005465A2 (https=) |
| CA (1) | CA3153644A1 (https=) |
| IL (1) | IL291730B2 (https=) |
| MX (1) | MX2022003065A (https=) |
| TW (1) | TW202126332A (https=) |
| WO (1) | WO2021067458A1 (https=) |
| ZA (1) | ZA202204162B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| WO2022103983A2 (en) * | 2020-11-11 | 2022-05-19 | Sutro Biopharma, Inc. | Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use |
| AU2022249281B2 (en) * | 2021-03-29 | 2025-08-14 | Aj Sciences (Yixing) Co., Ltd | Protein-macromolecule conjugates and methods of use thereof |
| CN113929731B (zh) * | 2021-12-16 | 2022-05-10 | 北京春雷杰创生物科技有限公司 | 一种促进低分子量蛋白体外复性和提高免疫原性的方法 |
| EP4539887A1 (en) * | 2022-06-16 | 2025-04-23 | Merck Sharp & Dohme LLC | Interleukin-2 prodrugs |
| CN115947745B (zh) * | 2022-12-26 | 2024-02-27 | 中山大学 | 一种基于白蛋白的光热转换纳米材料及其制备方法和应用 |
| CN120737012B (zh) * | 2025-08-29 | 2025-11-18 | 苏州金顶生物有限公司 | 一种新型保护氨基酸、制备方法及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| JP2013528593A (ja) | 2010-05-05 | 2013-07-11 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| JP2014531433A (ja) | 2011-09-07 | 2014-11-27 | プロリンクス エルエルシー | 生分解性架橋を有するヒドロゲル |
| JP2016534064A (ja) | 2013-10-22 | 2016-11-04 | プロリンクス エルエルシー | ソマトスタチン及びその類似体のコンジュゲート |
| WO2020219943A1 (en) | 2019-04-26 | 2020-10-29 | Prolynx Llc | Slow-release cytokine conjugates |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| DK1411075T3 (da) | 1998-03-12 | 2008-10-27 | Nektar Therapeutics Al Corp | Fremgangsmåde til fremstilling af polymerkonjugater |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
| US20070027073A1 (en) | 2003-04-08 | 2007-02-01 | Menachem Rubinstein | Long-acting derivatives of pyy agonists |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| BRPI0611872B8 (pt) | 2005-06-16 | 2021-05-25 | Nektar Therapeutics | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica |
| KR101508621B1 (ko) | 2007-02-28 | 2015-04-07 | 세리나 쎄라퓨틱스, 인코포레이티드 | 활성화된 폴리옥사졸린 및 이를 포함하는 조성물 |
| US7567215B1 (en) | 2007-10-23 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Navy | Portable and inflatable antenna device |
| CN104529711B (zh) | 2007-11-21 | 2020-02-07 | 乔治亚大学研究基金公司 | 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法 |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| US20100240773A1 (en) * | 2009-03-23 | 2010-09-23 | Kenneth Korzekwa | Multifunctional linkers |
| EP2566334B1 (en) * | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| WO2013036857A1 (en) * | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| US20140256626A1 (en) * | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
| WO2016053107A1 (en) * | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
-
2020
- 2020-09-30 CA CA3153644A patent/CA3153644A1/en active Pending
- 2020-09-30 BR BR112022005465A patent/BR112022005465A2/pt unknown
- 2020-09-30 EP EP20871115.0A patent/EP4037715A4/en active Pending
- 2020-09-30 US US17/764,475 patent/US20220401561A1/en active Pending
- 2020-09-30 IL IL291730A patent/IL291730B2/en unknown
- 2020-09-30 JP JP2022518653A patent/JP7784993B2/ja active Active
- 2020-09-30 KR KR1020227012420A patent/KR20220074897A/ko not_active Ceased
- 2020-09-30 AU AU2020360397A patent/AU2020360397A1/en active Pending
- 2020-09-30 WO PCT/US2020/053572 patent/WO2021067458A1/en not_active Ceased
- 2020-09-30 CN CN202080068415.6A patent/CN114630818A/zh active Pending
- 2020-09-30 TW TW109134302A patent/TW202126332A/zh unknown
- 2020-09-30 MX MX2022003065A patent/MX2022003065A/es unknown
-
2022
- 2022-04-12 ZA ZA2022/04162A patent/ZA202204162B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| JP2013528593A (ja) | 2010-05-05 | 2013-07-11 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| JP2014531433A (ja) | 2011-09-07 | 2014-11-27 | プロリンクス エルエルシー | 生分解性架橋を有するヒドロゲル |
| JP2016534064A (ja) | 2013-10-22 | 2016-11-04 | プロリンクス エルエルシー | ソマトスタチン及びその類似体のコンジュゲート |
| WO2020219943A1 (en) | 2019-04-26 | 2020-10-29 | Prolynx Llc | Slow-release cytokine conjugates |
Also Published As
| Publication number | Publication date |
|---|---|
| IL291730B2 (en) | 2026-02-01 |
| AU2020360397A1 (en) | 2022-03-31 |
| CA3153644A1 (en) | 2021-04-08 |
| IL291730B1 (en) | 2025-10-01 |
| WO2021067458A1 (en) | 2021-04-08 |
| MX2022003065A (es) | 2022-06-09 |
| EP4037715A4 (en) | 2023-12-13 |
| TW202126332A (zh) | 2021-07-16 |
| JP2022549295A (ja) | 2022-11-24 |
| ZA202204162B (en) | 2024-11-27 |
| KR20220074897A (ko) | 2022-06-03 |
| BR112022005465A2 (pt) | 2022-06-14 |
| CN114630818A (zh) | 2022-06-14 |
| EP4037715A1 (en) | 2022-08-10 |
| IL291730A (en) | 2022-05-01 |
| US20220401561A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7784993B2 (ja) | タンパク質－巨大分子コンジュゲート及びその使用方法 | |
| JP7104735B2 (ja) | Ｉｌ－２部分とポリマーとのコンジュゲート | |
| JP2021091708A (ja) | Ｉｌ−７部分とポリマーとのコンジュゲート | |
| US20240269293A1 (en) | Protein-macromolecule conjugates and methods of use thereof | |
| RU2845911C1 (ru) | Конъюгаты белок-макромолекула и способы их применения | |
| HK40067205A (en) | Protein-macromolecule conjugates and methods of use thereof | |
| HK40098591A (zh) | 蛋白-大分子缀合物及其使用方法 | |
| HK40053166A (en) | Conjugates of an il-2 moiety and a polymer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230929 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230929 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230929 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241004 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20241216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250404 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250702 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251104 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7784993 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |